|
The European Federation of Pharmaceutical Industries and Associations (EFPIA) is a Brussels-based trade association founded in 1978 representing the research-based pharmaceutical industry operating in Europe. Through its membership of 33 national associations and 40 leading pharmaceutical companies, EFPIA represents 1,900 EU companies committed to researching, developing and manufacturing new medical treatments. Figures published in 2008 by the European Commission ((Eurostat )) show that the pharmaceutical industry is the industrial sector which invests most in research & development (R&D). In 2011, it invested an estimated € 27,500 million in R&D in Europe. It directly employed 660,000 people and generated three to four times more employment indirectly (upstream and downstream). The key contribution of the research-based pharmaceutical industry to medical progress is to turn fundamental research into innovative treatments that are widely available and accessible to patients, with the goal of helping people live longer and be healthier. High blood pressure and cardiovascular disease can be controlled with anti-hypertensive medicines and cholesterol-lowering medicines, knee or hip replacements prevent patients from immobility, and some cancers can be controlled or even cured thanks to newer targeted medicines. Yet there remain huge challenges in many disease areas such as Alzheimer, multiple sclerosis, many cancers and orphan diseases. EFPIA also includes two specialised groups focusing on vaccines and biotechnology respectively: * Vaccines Europe ((EV )) produce approximately 80% of vaccines used worldwide. * European Biopharmaceutical Enterprises ((EBE )) harness biotechnology to develop approximately one-fifth of new medicines. ==EFPIA priorities== The industry's efforts are focused around four key areas - the AIMS - Roadmap of priorities Access, Innovation, Mobilization, Security () programme. * Access refers to the need to continue to work towards speeding up regulatory approval and reimbursement processes for new medicines; removing government controls on medicines that are not reimbursed; and ensuring that Health Technology Assessment (HTA) does not become a fourth hurdle to market access. * Innovation focuses on efforts towards creating a strong science base in Europe and making Europe an attractive location for the best researchers; ensuring a fair reward for innovation, including incremental innovation and ensuring a high level of protection for Intellectual Property Rights. * Mobilization is about joining forces with key stakeholders to address the challenges of an ageing population and deliver modern and sustainable healthcare; to fight damaging cost-containment policies; to empower patients and citizens to take an active role in managing their health through better access to information from multiple sources; to highlight industry's contribution to access to medicines and to promote new incentives for research into diseases affecting the developing world. * Security refers to the need to strengthen the integrity and transparency of the pharmaceutical supply chain by addressing the safety concerns of parallel trade; raising public awareness on the risk of counterfeits; and increasing the traceability of pharmaceutical products. 抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』 ■ウィキペディアで「European Federation of Pharmaceutical Industries and Associations」の詳細全文を読む スポンサード リンク
|